DGX שינוי ברווח נקי למניה בשנה הנוכחית questdiagnostics.com

Quest Diagnostics relies on stable demand for core tests, which guarantees a predictable cash flow. Comparing EPS with the same period last year visualizes this resilience, while 14.80 determines the latest valuation metric. Growth is driven by AI laboratory automation algorithms and an extensive network of insurance contracts that ensure customer retention.

This indicator measures the annual change in earnings per share, allowing investors to promptly identify a slowdown in capital growth rates between official reports. By analyzing the YoY earnings per share trend, one can assess the monetization efficiency of the massive volumes of laboratory tests performed by Quest Diagnostics (DGX) and paid for by the US healthcare system, which confirms the resilience of the company's fundamental health.